BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7127326)

  • 1. Phase II evaluation of bisantrene in patients with renal cell carcinoma.
    Myers JW; Von Hoff DD; Coltman CA; Kuhn JG; Van Echo D; Rivkin S; Pocelinko R
    Cancer Treat Rep; 1982 Oct; 66(10):1869-71. PubMed ID: 7127326
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of advanced non-small cell lung cancer with bisantrene.
    Fuks JZ; Van Echo DA; Garbino C; Kasdorf H; Aisner J
    Cancer Treat Rep; 1983 Jun; 67(6):597-8. PubMed ID: 6305499
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
    Evans WK; Shepherd FA; Blackstein ME; Osoba D; Taylor D
    Cancer Treat Rep; 1985 Jun; 69(6):727-8. PubMed ID: 4016779
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
    Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
    Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
    Myers JW; Von Hoff DD; Clark GM; Coltman CA
    Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II trial of bisantrene in advanced colorectal carcinoma.
    Ahmed T; Kemeny NE; Michaelson RA; Harper HD
    Cancer Treat Rep; 1983 Mar; 67(3):307-8. PubMed ID: 6831479
    [No Abstract]   [Full Text] [Related]  

  • 7. Bisantrene in non-small cell lung cancer: a phase II trial of the Cancer and Leukemia Group B.
    Green MR; Vosika G; Propert KJ; Ware JH; Comis R
    Cancer Treat Rep; 1986 Apr; 70(4):539-40. PubMed ID: 3698052
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I study of bisantrene in acute nonlymphoblastic leukemia.
    Marty M; Ferme C; Gisselbrecht C; Guy H; Clark MJ; Bancillon A; Boiron M
    Cancer Treat Rep; 1985 Jun; 69(6):703-5. PubMed ID: 4016773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group Study.
    Cowan JD; Surwit EA; Alberts DS; Boutselis JG; Neilan BA
    Cancer Treat Rep; 1986 Mar; 70(3):423-4. PubMed ID: 3955558
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II evaluation of pyrazofurin in patients with carcinoma of the lung.
    Gralla RJ; Currie VE; Wittes RE; Golbey RB; Young CW
    Cancer Treat Rep; 1978 Mar; 62(3):451-2. PubMed ID: 348315
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
    Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
    Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
    [No Abstract]   [Full Text] [Related]  

  • 12. Bisantrene, an active drug in patients with advanced breast cancer.
    Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
    Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study on DON in patients with previously treated advanced lung cancer.
    Eagan RT; Frytak S; Nichols WC; Creagan ET; Ingle JN
    Cancer Treat Rep; 1982 Aug; 66(8):1665-6. PubMed ID: 6286122
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II trial of bisantrene for unresectable non-small cell bronchogenic carcinoma: an Illinois Cancer Council study.
    McGuire WP; Blough RR; Cobleigh MA; Johnson CM; Kukla LJ; Lad TE; Lanzotti VJ; Stiff PJ; Zawila P
    Cancer Treat Rep; 1983 Sep; 67(9):841-2. PubMed ID: 6883363
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of bisantrene in hepatocellular carcinoma: a Southwest Oncology Group Study.
    Brown TD; Fleming TR; Shildt RA; Cowan JD
    Cancer Treat Rep; 1987 Nov; 71(11):1101-2. PubMed ID: 2824048
    [No Abstract]   [Full Text] [Related]  

  • 16. Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study.
    Vogelzang NJ; Lanzotti VJ; Muntean B; Blough RR
    Invest New Drugs; 1990 Aug; 8(3):313-5. PubMed ID: 2272771
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II trial of bisantrene in patients with metastatic melanoma.
    Mackel C; Meyskens FL; Alberts DS
    Cancer Treat Rep; 1986 Aug; 70(8):1037-8. PubMed ID: 3731151
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II trial of bisantrene in non-small cell lung cancer.
    Miller TP; Ahmann FR; Mackel C; Greenberg BR; Alberts DS
    Invest New Drugs; 1985; 3(4):393-5. PubMed ID: 4086247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of bisantrene for advanced hypernephroma.
    Scher H; Schwartz S; Yagoda A; Watson R; Faye L
    Cancer Treat Rep; 1982 Aug; 66(8):1653-5. PubMed ID: 7105056
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II study of deoxydoxorubicin in patients with advanced liver cancer.
    Perry DJ; Van Echo DA; Mick R
    Cancer Treat Rep; 1987 Nov; 71(11):1117-8. PubMed ID: 3119209
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.